Considerations around the scalability of automated cell therapy manufacturing

The hefty investment required to introduce automation to early-stage processes has traditionally spurred many in the field to postpone that decision. However, is the combination of technological innovation and a more informed sector beginning to turn the tide? David McCall (Senior Editor, BioInsights) speaks to Krishnendu Roy (Director, NSF Center for Cell Manufacturing Technologies and Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Technology, and starting August 1, 2023, the Bruce and Brigitt Evans Dean of Engineering at Vanderbilt University) about questions of scalability, and recent progress towards the goal of non-clean room GMP manufacturing with integrated process control for the cell therapy field.

Please enter your email to access content Read now